CLINICAL_TRIALS
trial_result
· 2020-09-03
Clinical Trial Update: Dose Ranging Study of Rimegepant (BMS-927711) for the Acute Treatment of Migraine [Phase 2]
Summary
Phase 2 dose-ranging trial of rimegepant (BMS-927711) for acute treatment of migraine has completed; results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Pfizer | Conditions: Migraine, Acute Treatment of Migraine | Phase 2 | Status: COMPLETED | Results posted: 2020-09-03